type 2 diabetes
Jan. 12, 2021—Discovering the mechanism behind cell behavior that is a hallmark of type 2 diabetes, Vanderbilt researchers move closer to treatments for the disease, which affects 34 million Americans.
Nov. 17, 2020—A study group of more than 600,000 patients with type 2 diabetes, identified from electronic medical records in the PCORnet national research network, could be valuable for assessing the safety of type 2 diabetes drugs.
Dec. 4, 2019—The identification of a protein important for insulin synthesis may hold clues for understanding the pathogenesis of diabetes.
Sep. 25, 2019—An observational study using medical record information from nearly 50,000 U.S. military veterans sheds new light on which drugs are best for patients with Type 2 diabetes and one of its common complications, kidney disease.
Jul. 20, 2018—A diabetes expert sorts myth from fact when it comes to type 2 diabetes.
Jan. 25, 2018—Researchers at Vanderbilt University have discovered how insulin crosses the capillary endothelium to exit blood vessels and stimulate skeletal muscle cells — a major finding that may lead to new ways to reverse insulin resistance, a hallmark of type 2 diabetes.
Jun. 22, 2017—In Middle Tennessee, where roughly one-third of children are overweight or obese, the risk of developing pediatric type 2 diabetes is high and the consequences can be serious.
May. 3, 2017—Vanderbilt investigators have identified novel regulators of insulin-producing beta-cell proliferation and survival, suggesting new targets for the treatment of type 2 diabetes.
Apr. 6, 2016—Adherence to medication was the only self-care activity independently associated with glycemic control in a low-income population.
Nov. 18, 2015—The growth factor FGF1 induces the growth of new insulin-producing beta cells and may help treat type 2 diabetes.
Oct. 16, 2014—Vanderbilt University researchers are closer to understanding the link between obesity, chronic inflammation and type 2 diabetes.
Jun. 12, 2014—In an observational study by researchers at Vanderbilt University Medical Center, adults with type 2 diabetes who take insulin in addition to the recommended first-line drug therapy, metformin, had a 30 percent higher risk of heart attack, stroke or death when compared to similar patients who instead augment their metformin regimen with a sulfonylurea.